155 results on '"Ning Shao"'
Search Results
2. Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial
3. Major HBV splice variant encoding a novel protein important for infection
4. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial
5. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
6. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial
7. Data from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
8. Data from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
9. Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
10. Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
11. Supplementary Table 1 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
12. Supplementary Legends from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
13. Supplementary Legends from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
14. Supplementary Table 1 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
15. Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
16. Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
17. Ultrafast Microfluidic PCR Thermocycler for Nucleic Acid Amplification
18. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19
19. Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial
20. Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study
21. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
22. Prognosis of hepatitis E infection in patients with chronic liver disease: A meta‐analysis
23. An Optimized FI-RSV Vaccine Effectively Protects Cotton Rats and BALB/c Mice without Causing Enhanced Respiratory Disease
24. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
25. Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
26. Recent progress in antibody-based therapeutics for triple-negative breast cancer
27. Molecular Evolution of Attachment Glycoprotein (G) and Fusion Protein (F) Genes of Respiratory Syncytial Virus ON1 and BA9 Strains in Xiamen, China
28. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
29. Machine Learning for Structure Determination in Single-Particle Cryo-Electron Microscopy: A Systematic Review
30. A cell-penetrating whole molecule antibody targeting intracellular HBx suppresses hepatitis B virus via TRIM21-dependent pathway: Erratum
31. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma
32. Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy
33. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition
34. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
35. Study on the p-type ohmic contact in GaAs-based laser diode
36. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
37. Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection
38. Nanospheres from coordination polymers of Ag+ with a highly hydrophilic thiol ligand formed in situ from dynamic covalent binding and a hydrophobic thiol
39. Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response
40. The effect of economic policy uncertainty on China’s housing market
41. Early diagnosis and population prevention of coronavirus disease 2019
42. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans
43. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases
44. Naturally occurring 5′ preS1 deletions markedly enhance replication and infectivity of HBV genotype B and genotype C
45. Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections in Close Contacts of Coronavirus Disease 2019 (COVID-19) Patients: A Seroepidemiological Study
46. MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer
47. Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro
48. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset
49. Serological Test is an Efficient Supplement for Detecting RNA to Confirm SARS-CoV-2 Infection
50. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.